Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres

Journal of Drug Targeting

Volumn 18, Issue 3, 2010, Pages 212-222

  Saini, Vinay ^a   Jain, Vikas ^a   Sudheesh, M S ^a   Dixit, Saurabh ^b   Gaur, R L ^b   Sahoo, M K ^b   Joseph, S K ^b   Verma, S K ^b   Jaganathan, K S ^c   Murthy, P K ^b   Kohli, Dharmveer ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

^c Shantha Biotechnics Limited   (India)

Author keywords

Hepatitis B; Immunoglobulins; Lymphocyte transformation test; Microspheres; Nitric oxide; Th1 cytokines

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AMMONIUM DERIVATIVE; CATION; CETYLTRIMETHYAMMONIUMBROMIDE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; MICROSPHERE; NITRIC OXIDE; POLYLACTIDE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ADSORPTION; DRUG STABILITY; HUMORAL IMMUNITY; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ANIMALS; CATIONS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EMULSIONS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; PARTICLE SIZE; POLYESTERS;

EID: 77949377692     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903386920     Document Type: Article

References (42)

1. Absolom DR, Zingg W, Neumann AW. (1987). Protein adsorption to polymer particles: role of surface properties. J Biomed Mater Res, 21(2): 161-171.
2. Bos GW, Kanellos T, Crommelin DJ, Hennink WE, Howard CR. (2004). Cationic polymers that enhance the performance of HbsAg DNA in vivo. Vaccie, 23: 460-469.
3. Cleland JL. (1999). Single-administration vaccines: controlled release technology to mimic repeated immunizations. Trends Biotechnol, 17: 25-29.
4. Coombes AG, Lavelle EC, Davis SS. (1999). Biodegradable lamellar particles of poly(lactide) induce sustained immune responses to a single dose of adsorbed protein. Vaccine, 17: 2410-2422.
5. Coombes AG, Lavelle EC, Jenkins PG, Davis SS. (1996). Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine, 14: 1429-1438.
6. Coombes AG, Major D, Wood JM, Hockley DJ, Minor PD, Davis SS. (1998). Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Biomaterials, 19: 1073-1081.
7. Dixit S, Gaur RL, Sahoo MK, Joseph SK, Murthy PS, Murthy PK. (2006). Protection against L3 induced Brugia malayi infection in Mastomys coucha pre-immunized with BmAFII fraction of the filarial adult worm. Vaccine, 24: 5824-5831.
8. Eallen J, Loke P. (2001). Divergent roles for macrophages in lymphatic filariasis. Parasite Immunol, 23: 345-352.
9. Elias F, Flo J, Rodriguez JM, Nichilo AD, Lopez RA, Zorzopulos J. (2003). PyNTTTTGT prototype oligonucleotide IMT504 is a potent adjuvant for the recombinant hepatitis B vaccine that enhances the Th1 response. Vaccine, 23: 3597-3603.
10. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, Nagai T. (2006). Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.J Control Release, 112: 35-42.
11. Ghaffari A, Miller CC, McMullin B, Ghahary A. (2006). Potential application of gaseous nitric oxide as a topical antimicrobial agent. Nitric Oxide, 14: 21-29.
12. Goldsby RA, Kindt TJ, Osborne BA. (2007). Antigens and Antibodies. In: Kuby Immunology, 6th ed. (pp. 96-97). New York, W.H. Freeman and Company.
13. Guidotti LG, McClary H, Loudis JM, Chisari FV. (2000). Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med, 191: 1247-1252.
14. Gupta RK, Alroy J, Alonso MJ, Langer R, Siber GR. (1997). Chronic local tissue reactions, long-term immunogenicity and immunologic priming of mice and guinea pigs to tetanus toxoid encapsulated in biodegradable polymer microspheres composed of poly lactide-co-glycolide polymers. Vaccine, 15: 1716-1723.
15. Gupta RK, Singh M, O'Hagan DT. (1998). Poly(lactide-co-glycolide) microparticles for the development of single-dose controlledrelease vaccines. Adv Drug Deliv Rev, 32: 225-246.
16. Langer R, Cleland JL, Hanes J. (1997). New advances in microspherebased single-dose vaccines. Adv Drug Deliv Rev, 28: 97-119.
17. Hilleman MR. (2003). Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine, 21: 4626-4649.
18. Jabbal-Gill I, Lin W, Jenkins P, Watts P, Jimenez M, Illum L. (1999). Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines. Vaccine, 18: 238-250.
19. Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. (2004). Development of a single-dose stabilized poly(D,L-lactic-coglycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol, 56: 1243-1250.
20. Jaganathan KS, Vyas SP. (2006). Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine, 24: 4201-4211.
21. Johansen P, Gander B, Merkle HP, Sesardic D. (2000). Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol, 18: 203-211.
22. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. (2000). Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release, 67: 347-356.
23. Lavelle EC, Yeh MK, Coombes AG, Davis SS. (1999). The stability and immunogenicity of a protein antigen encapsulated in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. Vaccine, 17: 512-529.
24. McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. (1999). Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine.Vaccine, 17: 330-339.
25. Men Y, Gander B, Merkle H P, Corradin G (eds.). 1997. Antigen Delivery Systems: Immunological and Technological Issues, Australia: Harwood Academic Publishers, 8: 191-205.
26. Mishra D, Dubey V, Asthana A, Saraf DK, Jain NK. (2006). Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine, 24: 4847-4855.
27. Moynihan JS, Blair J, Coombes A, D'Mello F, Howard CR. (2002). Enhanced immunogenicity of a hepatitis B virus peptide vaccine using oligosaccharide ester derivative microparticles. Vaccine, 20: 1870-1876.
28. O'Hagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K, Paliard X, Coates S, Houghton M. (2004). Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine, 23: 672-680.
29. Oster CG, Kim N, Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SH, Kissel T. (2005). Cationic microparticles consisting of poly(lactide-co- glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release, 104: 359-377.
30. Panyam J, Dali M M, Sahoo S K, Ma W, Chakravarthi SS, Amidon GL, Levy RJ. (2003). polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano-and microparticles. J Control Rel, 92: 173-187.
31. Rafati H, Lavelle EC, Coombes AG, Stolnik S, Holland J, Davis SS. (1997). The immune response to a model antigen associated with PLG microparticles prepared using different surfactants. Vaccine, 15: 1888-1897.
32. Raychaudhuri S, Rock KL. (1998). Fully mobilizing host defense: building better vaccines. Nat Biotechnol, 16: 1025-1031.
33. Saraf S, Mishra D, Asthana A, Jain R, Singh S, Jain NK. (2006). Lipid microparticles for mucosal immunization against hepatitis B. Vaccine, 24: 45-56.
34. Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J. (1995). Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. Vaccine, 13: 857-865.
35. Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. (2002). Pharmaceutical and immunological evaluation of a singleshot hepatitis B vaccine formulated with PLGA microspheres. J Pharm Sci, 91: 1019-1035.
36. Singh M, Briones M, Ott G, O'Hagan D. (2000). Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA, 97: 811-816.
37. Stivaktakis N, Nikou K, Panagi Z, Beletsi A, Leondiadis L, Avgoustakis K. (2005). Immune responses in mice of β-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly (lactic-co-glycolic acid) microspheres. Wiley Periodical Inc: 332-338.
38. Venkataprasad N, Coombes AGA, Singh M, Rohde M, Wilkinson K, Hudecz F. (1999). Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine, 17: 1814-1819.
39. Vordermeier HM, Coombes AGA, Jenkins P, McGee JP, O'Hagan DT, Davis SS. (1995). Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine, 13: 1576-1582.
40. Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR. (2006). Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release, 114: 359-368.
41. Witschi C, Doelker E. (1998a). Peptide degradation during preparation and in-vitro release testing of PLA and PLGA microparticles. Int J Pharm, 171: 1-18.
42. Witschi C, Doelker E. (1998b). Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lacticco-glycolic acid) degradation during in vitro testing. J Control Release, 51: 327-341.